Haisco Pharmaceutical

News

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

News

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.